NCT03158233 is a clinical trial in Zika Virus Disease, sponsored by Sanofi Pasteur, a Sanofi Company.

Who is sponsoring NCT03158233?

NCT03158233 is sponsored by Sanofi Pasteur, a Sanofi Company.

What condition does NCT03158233 study?

NCT03158233 studies Zika Virus Disease.

Is NCT03158233 still recruiting?

NCT03158233 is currently completed. Last updated 25 April 2022.

Last reviewed 2022-04-25 · How we verify

NCT03158233

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Zika Case Definition and Surveillance Study

Completed Last updated 25 April 2022

What this trial tests

trial in Zika Virus Disease in 2,400 participants. Completed in 19 December 2018.

Timeline

29 April 2017

Primary endpoint
19 December 2018

19 December 2018

Quick facts

Lead sponsor	Sanofi Pasteur, a Sanofi Company
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,400
Start date	29 April 2017
Primary completion	19 December 2018
Estimated completion	19 December 2018
Sites	6 locations across Colombia, Puerto Rico, Mexico, Honduras

Conditions studied

Zika Virus Disease — all drugs for Zika Virus Disease →

Sponsor

Sanofi Pasteur, a Sanofi Company — full company profile →

Who can join

Adults 15 to 40, any sex, with Zika Virus Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective, surveillance study will assess the operational Zika virus definition for use in future Zika purified inactivated virus (ZIKV) vaccine efficacy trials in order to identify Zika virus disease (ZVD) cases among the study cohort.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Sanofi Pasteur, a Sanofi Company trials

Trials by the same sponsor.

NCT07536048 — A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years · not yet recruiting
NCT07222059 — Phase 3 Single Arm, Open Study on vYF in Adults · Phase 3 · completed
NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
NCT06793826 — Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03158233 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sanofi Pasteur, a Sanofi Company
Last refreshed: 25 April 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03158233.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing